A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Full Text
The Oncologist,  Clinical Article

Hurwitz H et al. – Based on the results, the first–line treatment of U.S. patients with metastatic colorectal cancer (mCRC) using a biweekly combination of Capecitabine administered for 7days biweekly with oxaliplatin (XELOX) and bevacizumab at the doses studied cannot be recommended. XELOX triweekly cycle (Q3W) remains the preferred schedule for the management of mCRC.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore